

Epilepsies in children, young people and adults

Committee meeting 06

Date: 28 January 2020

Location: Boardroom, NGC Offices, Royal College of Physicians, 11 St. Andrews Place, Regent's Park, London, NW1 4LE

Minutes: Final

Committee members	s present:			
Stephen Ward (Chair)	Present for notes 1 – 12			
Arjune Sen (Topic ad	viser)	Present for notes 1 – 12		
Christina Petropoulos		Present for notes 1 – 12		
Janine Winterbottom		Present for notes 1 – 12		
Jon Mark Dickson		Present for notes 1 – 12		
Lisa O'Brien		Present for notes 1 – 12		
Phillip Smith		Present for notes 1 – 12		
Rohit Shankar	Present for notes 1 – 12			
Lauren Anderson	Present for notes 1 – 12			
Sally Gomersall	Present for notes 1 – 12			
Sallie Baxendale		Present for notes 1 – 12		
Archana Desurkar		Present for notes 1 – 12		
Susan Croft (co-opted	l committee member)	Present for notes 1 – 12		
Trudy Thomas		Present for notes 1 – 12		
In attendance:				
Angela Cooper	Senior research fellow	Present for notes 1 – 12		
Gill Ritchie	Guideline lead	Present for notes 1 – 12		
Margaret Constanti	Senior health economist	Present for notes 1 – 12		
Joseph Runicles	Information Specialist	Present for notes 11 – 12		
Rafina Yarde	Research fellow	Present for notes 1 – 12		
Tamara Diaz	Project manager	Present for notes 1 – 12		
Caroline Keir	NICE Guideline Commissioning Manager (attended via Skype)	Present for notes 1 – 12		
Catharine Baden- Daintree	NICE Editor	Present for notes 1 – 12		
Apologies:				
Ashifa Trivedi (co-opt	ed committee member)			
Ashley Liew (co-opted	d committee member)			
Gabriella Rands				

1. Welcome and objectives for the meeting

The Chair welcomed attendees to the sixth meeting of the Epilepsies in children, young people and adults Guideline Committee.

The Chair informed the Committee that there had been apologies from Ashley Liew and Ashifa Trivedi. These are noted on the attendees list.

The Chair outlined the objectives of the meeting, which included:

- Review of evidence discussion documents for:
 - Reducing the risk of seizure-related mortality, including Sudden Unexpected Death in Epilepsy (SUDEP), in people with epilepsy
- Presenting and discussing clinical and health economic evidence on
 - Status Epilepticus monotherapy
 - Status Epilepticus add on therapies
 - Repetitive or cluster seizures monotherapy
 - o Repetitive or cluster seizures add on therapies
 - Prolonged seizures monotherapy
- Presenting, discussing and editing draft review protocols.

2. Declarations of interest: committee declarations

The Chair confirmed the matters under discussion, for the purpose of managing conflicts of interest, and asked attending Committee members to verbally declare any interests that may have arisen since the last meeting. Previously declared conflict by Philip Smith repeated as Status Epilepticus will be

discussed on the day's agenda. No further action required.

All interests declared during the meeting are noted below:

Name	Job title, organisation	Declarations of Interest, when declared (Meeting/Recruitment)	Type of interest	Decision taken
Arjune Sen	Topic Advisor	Speaker honoraria for meeting hosted by Bial Pharma. Delivered talk on topic of epilepsy and ageing.	In-Direct Financial	Declare and participate.
		Speaker honoraria for meeting hosted by UCB Pharma. Delivered talk on epilepsy and dementia	In- Direct Financial	Declare and participate.
Rohit Shankar	Learning disabilities psychiatrist	Chief Investigator Neuronostics (NIHR Adopted) funded by Innovate grant. December 2019 ongoing	In-Direct Financial	Declare and participate.
		UCB IIS grant for Ep-ID national register (NIHR adopted) –Chief investigator	In-Direct Financial	Declare and participate.



		January 2020 Ongoing		
		RSM invited talk SUDEP & ID	Direct non-	Declare
		– no honorarium 11.11.2019	Financial	and
				participate.
		UCB talks on Lacosamide and	In-Direct	Declare
		ID from Ep-ID Register	Financial	and
		findings – all honorarium paid		participate.
		to NHS Trust		
		19.11.2019		
		09.12.2019		
		Bristol Medical cannabis	Direct non-	Declare
		conference talk on epilepsy	Financial	and
		and cannabis – no honorarium		participate.
		28.11.2019		
		RCPsych workshop in Belfast	Direct non-	Declare
		- no honorarium 6.12.2019	Financial	and
				participate.
		Advisory committee member	Direct	Declare
		ational Confidential Enquiry	Financial	and
		into Patient Outcome and		participate.
		Death (NCEPOD) 08.01.2020		
		ongoing		
		NIHR grant (co-applicant)	In-Direct	Partial
		SUDEP seizure safety	Financial	exclusion
		communication 04.12.2019		for the
		ongoing		SUDEP
				risk factors
				question
				tbc
Philip	Adult	Editorial on Status epilepticus	Direct Non-	Declare
Smith	Neurologist	has been published in the New	Financial	and
		England Journal of Medicine.		participate
Christina	Neurological	Co-Author – "Practical aspects	Direct	Declare
Petropoulos	Surgeon	of childhood epilepsy	non-	and
		BMJ 2019; 367 doi: https://doi.	Financial	participate
		org/10.1136/bmj.l6096 (Publis		
		hed 11 November 2019) – My		
		original contribution was		
		before joining the committee		
		Talk given to group of GPs	Direct	Declare
		"Paediatric Epilepsy What GPs	non-	and
		need to know" – unpaid	Financial	participate

The Chair and a senior member of the Developer's team noted that the above interests, declared during the meeting, did not prevent attendees from fully participating in the day's meeting.

3. Minutes of the previous meeting

The GC approved the minutes of Guideline Committee meeting 4.

4. Draft discussion documents

The group's discussion of evidence related to the following topic, had been summarised and circulated for their consideration:

• Interventions to reduce seizure related mortality including SUDEP This item was agreed as an accurate reflection of meeting discussions.

5. NICE Editor's Presentation: drafting recommendations

A presentation on drafting recommendations was given for the committee's information.

6. Draft Review: Status epilepticus monotherapy

The evidence was presented for the following clinical question: What antiepileptic drugs (monotherapy) are effective in the treatment of status epilepticus? The committee considered and discussed the evidence.

7. Draft Review: Status epilepticus add on

The evidence was presented r for the following clinical question: What antiepileptic drugs (add-on therapy) are effective in the treatment of status epilepticus? The committee considered and discussed the evidence.

8. Draft Review: Repetitive or cluster seizures monotherapy

The evidence was presented for the following clinical question: What AEDs (monotherapy) are effective in the treatment of repeated seizures or clusters of seizures? The committee considered and discussed the evidence.

9. Draft Review: Repetitive or cluster seizures monotherapy

The evidence was presented for the following clinical question: What AEDs (add-on therapy) are effective in the treatment of repeated seizures or clusters of seizures? The committee considered and discussed the evidence.

10. Draft Review: Prolonged seizures

The evidence was presented for the following clinical question: What AEDs (monotherapy) are effective in the treatment of prolonged seizures? . The committee considered and discussed the review question.

11. Draft review protocols

The committee discussed and amended the draft review protocol on:

When should monitoring be carried out for people with epilepsy? How should monitoring be carried out for people with epilepsy, and who should do it?

12. Any other business

There being no further business the meeting ended at 1600.

Date of next meeting:	*24 March 2020
	25 March 2020
	*(At a later date, post meeting, the committee were advised of the subsequent cancellation of the meeting scheduled for 24 March)
Location of next meeting:	NGC Board room, Royal College of Physicians